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In CRT-Eligible Heart Failure Patients with no 
History of Ventricular Arrhythmias, Addition of 
ICD Conveys Survival Benefit in Patients with 
Ischemic Cardiomyopathy (CM) but not in Those 
with Nonischemic CM  
According to an observational, multicenter, European 
cohort study of 5,307 consecutive patients with dilated or 
ischemic CM, no history of sustained ventricular 
arrhythmias, who underwent CRT implantation with 
(n=4,037) or without (n=1,270) a defibrillator, over 41.4 ± 
29.0 months, patients with ischemic (not dilated) CM had 
better survival when receiving CRT-D compared with 
those who received CRT-P (hazard ratio-HR: 0.76; 
p=0.005). Compared with recipients of ICD, the excess 
mortality in patients who did not receive ICDs was related 
to sudden cardiac death in 8% among those with ischemic 
CM but in only 0.4% of those with dilated CM (Barra S et 
al, J Am Coll Cardiol 2017; 69:1669-1678).   
SELECT-LV Study: In a Population of Failed 
Conventional CRT Patients, Cardiac Resynchroniza-
tion With Endocardial LV Stimulation via a Novel 
Leadless Pacing Electrode was Technically Feasible 
and Efficacious  
Among 35 patients indicated for CRT who had “failed” 
conventional CRT, implantation of an LV endocardial 
leadless pacing electrode and a subcutaneous pulse 
generator was successful in 97.1% (n=34). The most 
common indications for endocardial LV pacing were 
difficult CS anatomy (n=12), failure to respond to 
conventional CRT (n=10), and a high CS pacing threshold 
or phrenic nerve stimulation (n=5). The primary 
performance endpoint, biventricular pacing on the 12-lead 
ECG at 1 month, was achieved in 33 of 34 patients. A total 
of 28 patients (84.8%) had improvement in the clinical 
composite score at 6 months, and 21 (66%) demonstrated 
a positive echocardiographic CRT response (≥5% absolute 
increase in LV ejection fraction). There were no 
pericardial effusions, but serious procedure/device-related 
events occurred in 3 patients (8.6%) within 24 h, and 8 
patients (22.9%) between 24 h and 1 month (Reddy VY et 
al, J Am Coll Cardiol 2017;69:2119-29).   
Improvements in both Survival and Heart Failure 
Hospitalizations with CRT-D were Greatest in Patients 
with a QRSD ≥180 ms with or without LBBB  
Analysis of 24,960 patients receiving CRT-D and 
matched to patients with ICD indicated that among those 
with LBBB, patients with a QRSD ≥180 ms had a greater 
survival benefit with CRT-D vs standard ICD (hazard 
ration -HR for death: 0.65) compared with those having a 
QRSD 120 to 149 ms (HR: 0.85) and 150 to 179 ms (HR: 
0.87). CRT-D vs ICD was associated with an improvement 
in survival in those with non-LBBB and a QRSD≥180 ms 
(HR for death: 0.78), but not in those with non-LBBB and 
a QRSD 150 to 179 ms (HR for death: 1.06) (Sundaram V 
et al, J Am Coll Cardiol 2017;69: 2026–36).   
PARTNER 2 Valve-in-Valve (VIV) Registry: Use of 
VIV TAVI for High-Risk Patients With Degenerated 
Aortic Bioprostheses Confers Relatively Low Rates of 
Mortality and Major Complications, Improved 
Hemodynamics and Functional and Quality of Life 
(QOL) Outcomes at 1 Year  
VIV procedures were performed in 365 patients (age 
78.9 ± 10.2 years, STS score 9.1 ± 4.7%) At 30 days, all-
cause mortality was 2.7%, stroke 2.7%, major vascular 
complication 4.1%, conversion to surgery 0.6%, coronary 
occlusion 0.8%, and new pacemaker insertion 1.9%. One-
year all-cause mortality was 12.4%. Mortality fell from the 
initial registry to the subsequent continued access registry, 
both at 30 days (8.2% vs 0.7%; p=0.0001) and at 1 year 
(19.7% vs 9.8%; p=0.006). At 1 year, mean gradient was 
17.6 mmHg, and effective orifice area was 1.16 cm2, with 
greater than mild paravalvular regurgitation of 1.9%. Left 
ventricular ejection fraction increased (50.6% to 54.2%), 
and mass index decreased (135.7 to 117.6 g/m2), with 
reductions in both mitral (34.9% vs 12.7%) and tricuspid 
(31.8% vs 21.2%) moderate or severe regurgitation (all 
p<0.0001). QOL improved and 6-min walk test distance 
results increased (mean: 163.6 to 252.3 m; both p< 0.0001) 
(Webb JG et al, J Am Coll Cardiol 2017;69:2253-62).   
Patients with Concomitant Moderate Aortic Stenosis 
(AS) and LV Systolic Dysfunction are at High Risk for 
Clinical Events  
At 4 years, among 305 patients (mean age 73±11 years; 
75% male; 72% with ischemic heart disease) with 
moderate AS (aortic valve area of 1-1.5 cm2) and LV 
systolic dysfunction (ejection fraction <50%), with the 
majority being symptomatic at the time of index 
echocardiogram (NYHA class II: 42%; class III: 28%; and 
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class IV: 4%), the primary composite endpoint (all-cause 
death, AVR, and HF hospitalization) occurred in 61%. The 
main predictors for the primary endpoint were male sex 
(p=0.022), NYHA functional class III or IV (p< 0.001), 
and peak aortic jet velocity (p< 0.001). The rate of the 
composite of all-cause death or heart failure (HF) 
hospitalization was 48%, rate of all-cause death was 36%, 
and rate of HF hospitalization was 27%. Aortic valve 
replacement (AVR) occurred in 24% of patients (van Gils 
L J et al, J Am Coll Cardiol 2017;69:2383-92).  
RIVER-PCI Trial: Ranolazine Significantly Lowered 
HbA1c and Lessened the New Onset of DM in Patients 
With and Without DM / Ranolazine was More Effective 
at Reducing Angina Frequency at 6 Months (but not 12 
Months) in Patients With Diabetes With HbA1c≥7.5% 
and Incomplete Revascularization, Suggesting a 
Possible Synergy Between the Drug’s Effect on Angina 
and Glucose Control  
Among 2,604 patients with chronic angina and 
incomplete revascularization via PCI randomized to 
ranolazine vs placebo (961 or 36.9% having DM at 
baseline), ranolazine, compared with placebo, significant-
ly decreased HbA1c by 0.42±0.08% and 0.44 ± 0.08% from 
baseline to 6 and 12 months, respectively, in DM patients, 
and by 0.19 ± 0.02% and 0.20 ± 0.02% at 6 and 12 months, 
respectively, in non-DM patients. Compared with placebo, 
ranolazine significantly reduced angina frequency at 6 
months among DM patients but not at 12 months. The 
reductions in angina frequency were greater among 
patients with baseline HbA1c ≥7.5% (interaction p=0.07) 
(Fanaroff AC et al, J Am Coll Cardiol 2017;69: 2304-13).   
Compared with Tricuspid Aortic Stenosis (AS), TAVI 
in Bicuspid AS was Associated with a Similar 
Prognosis, but a Lower Device Success Rate / Results 
were Improved with New Generation Devices  
Among 561 patients with bicuspid AS and 4,546 
patients with tricuspid AS, comparison of 546 propensity 
score matched pairs indicated that bicuspid AS had more 
frequent conversion to surgery (2% vs 0.2%; p=0.006) and 
a significantly lower device success rate (85.3% vs 91.4%; 
p=0.002). Within the group receiving early-generation 
devices, bicuspid AS had more frequent aortic root injury 
(4.5% vs 0%; p=0.015) when receiving the balloon-
expanding device, and moderate-to-severe paravalvular 
leak (19.4% vs 10.5%; p=0.02) when receiving the self-
expanding device. Among patients with new-generation 
devices, however, procedural results were comparable 
across different prostheses. The cumulative all-cause 
mortality rates at 2 years were comparable between 
bicuspid and tricuspid AS (17.2% vs 19.4%; p=0.28) 
(Yoon SH et al, J Am Coll Cardiol 2017;69:2579-89).   
Among Patients Surviving Hospitalization With AMI 
Without Heart Failure (HF) or LV Systolic 
Dysfunction (LVSD) (EF<30%), β-Blocker Use did not 
Confer Lower All-Cause Mortality up to 1 Year  
Among 179,810 survivors of hospitalization with AMI 
without HF or LVSD, 91,895 patients with STEMI and 
87,915 with non–STEMI, 88,542 (96.4%) and 81,933 
(93.2%) received β-blockers, respectively. For the entire 
cohort, there were 9,373 deaths (5.2%). Unadjusted 1-year 
mortality was lower for patients who received β-blockers 
compared with those who did not (4.9% vs 11.2%; p < 
0.001). However, after weighting and adjustment, there 
was no significant difference in mortality between those 
with and without β-blocker use (p=NS). Findings were 
similar for STEMI (p=0.637) and non–STEMI (p=0.819) 
(Dondo TB et al, J Am Coll Cardiol 2017;69:2710-20). 
N.B.: LVEF cutoff for systolic dysfunction was 30%.   
DANAMI-3–DEFER CMR Substudy: Deferred 
Stenting did not Reduce Infarct Size or the Occurrence 
of Microvascular Obstruction (MVO) and did not 
Improve Myocardial Salvage  
Among 510 STEMI patients randomized to PCI with 
deferred vs immediate stent implantation, deferred stenting 
did not reduce final infarct size (p = 0.67). Similarly, 
deferred stenting was not associated with myocardial 
salvage index (p = 0.80) or presence of MVO (43% vs. 
42%; p = 0.78). In a post hoc analysis, stent length was the 
only subgroup of 7 that had an effect on outcome. In 
patients with a stent length ≥24 mm, deferred stenting 
reduced the final infarct size (p = 0.006) (Lonborg J et al, 
J Am Coll Cardiol 2017;69: 2794-2804).   
DAPT Study: Discontinuing Thienopyridine after 12 or 
30 Months Increases Early MI risk, Mainly Unrelated 
to Stent Thrombosis 
Among the 11 648 randomly assigned patients, the 
monthly cumulative incidence of MI was lower with 
continued thienopyridine vs placebo at 12-15 months 
(0.12% vs 0.37%, P<0.001, in all patients; 0.13% vs 
0.27%, P=0.02, in patients not treated with paclitaxel-
eluting stents), and higher at 30-33 months (0.30% vs 
0.15%, P=0.013, in all patients; in patients without 
paclitaxel-eluting stents, 0.18% vs 0.17%, P=0.91). The 
majority of MIs in both time periods (74% and 76%) were 
not related to stent thrombosis (Stefanescu AC et al, 
Circulation 2017;135:1720-32).   
Safety Analysis of Evolocumab in 6026 Patients Pooled 
Across Phase 2/3 Trials & 4465 Patients who Continued 
in Open Label Extension Trials for 1 Year Supports a 
Favorable Benefit-Risk Profile for Evolocumab 
Overall adverse event (AE) rates were similar between 
evolocumab and control in the parent trials (51.1% vs 
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49.6%) and in year 1 of open label extension (OLE) trials 
(70% vs 66%), as were those for serious AEs. Elevations 
of serum transaminases, bilirubin, and creatine kinase were 
infrequent and similar between groups. Muscle-related 
AEs were similar between evolocumab and control. 
Neurocognitive AEs were infrequent and balanced during 
the double-blind parent studies. In the OLE trials, 27 
patients (0.9%) in the evolocumab groups and 5 patients 
(0.3%) in the control groups reported neurocognitive AEs. 
No neutralizing antievolocumab antibodies were detected 
(Toth PP et al, Circulation 2017;135:1819-31).   
OCEAN Japanese Multicenter Registry: In Addition to 
Reflecting the Degree of Frailty, the Clinical Frailty 
Scale (CFS) was a Useful Marker for Predicting Late 
Mortality in an Elderly TAVI Cohort of 1215 Patients 
The semiquantitative Clinical Frailty Scale (CFS) grade 
showed significant correlation with body mass index 
(Spearman’s ρ=−0.077, P=0.007), albumin (ρ=−0.22, 
P<0.001), gait speed (ρ=−0.28, P<0.001), and grip 
strength (ρ=−0.26, P<0.001). Cumulative 1-year mortality 
increased with increasing CFS stage (7.2%, 8.6%. 15.7%, 
16.9%, 44.1%, P<0.001). In a Cox regression multivariate 
analysis, the CFS (per 1 category increase) was an 
independent predictive factor of increased late cumulative 
mortality risk (hazard ratio, 1.28; P<0.001) (Shimura T et 
al, Circulation 2017;135:2013-24.  
Midwall Late Gadolinium Enhancement (LGE) 
Identifies a Group of Patients With Dilated 
Cardiomyopathy (DCM) and an LVEF ≥40% at 
Increased Risk of SCD and Low Risk of Nonsudden 
Death Who May Benefit from ICD Implantation 
Of 399 DCM patients with LVEF >40% (145 women, 
median age 50 years, median LVEF 50%, 25.3% with 
LGE) followed for a median of 4.6 years, 18 of 101 
(17.8%) patients with LGE reached the prespecified end 
point (SCD or aborted SCD), compared with 7 of 298 
(2.3%) without (hazard ratio -HR, 9.2; P<0.0001). Nine 
patients (8.9%) with LGE compared with 6 (2%) without 
(HR, 4.9; P=0.002) died suddenly, whereas 10 patients 
(9.9%) with LGE compared with 1 patient (0.3%) without 
(HR, 34.8; P<0.001) had aborted SCD. After adjustment, 
LGE predicted the composite end point (HR, 9.3; 
P<0.0001), SCD (HR, 4.8; P=0.003), and aborted SCD 
(HR, 35.9; P<0.001) (Halliday BP et al, Circulation 
2017;135:2106-15).   
Drone Delivered AEDs Come to the Rescue in Out-Of-
Hospital Cardiac Arrest  
Drones can deliver an automatic external defibrillator 
(AED) to the scene of an out-of-hospital cardiac arrest for 
bystander use. This model was applied to 53 702 out-of-
hospital cardiac arrests in Toronto. It was determined that 
81 bases and 100 drones would be required to deliver an 
AED ahead of median 911 response times by 3 minutes. In 
the most urban region, the 90th percentile of the AED 
arrival time was reduced by 6 min and 43 sec relative to 
historical 911 response times in the region. In the most 
rural region, the 90th percentile was reduced by 10 min and 
34 sec. A single coordinated drone network across all 
regions required 39.5% fewer bases and 30% fewer drones 
to achieve similar AED delivery times (Boutilier JJ et al, 
Circulation 2017;135:2454-65).   
SURTAVI: TAVI Noninferior to Surgery in Patients 
With Severe Aortic Stenosis (AS) at Intermediate 
Surgical Risk, With a Different Pattern of Adverse 
Events Associated With Each Procedure 
Among 1746 intermediate-risk (STS 4.5+1.6%) 
patients with severe symptomatic AS undergoing 
randomization, 1660 (age 80+6) underwent an attempted 
TAVI (self-expanding valve) or surgical procedure. At 24 
months, the estimated incidence of the primary end point 
(death from any cause or disabling stroke) was 12.6% in 
the TAVI group and 14% in the surgery group. Surgery 
was associated with higher rates of acute kidney injury, 
AF, and transfusion requirements, whereas TAVI had 
higher rates of residual aortic regurgitation and need for 
pacemaker implantation. TAVI resulted in lower mean 
gradients and larger aortic-valve areas than surgery. 
Structural valve deterioration at 24 months did not occur 
in either group (Reardon MJ et al, N Engl J Med 2017; 
376:1321-1331).  
RE-CIRCUIT: In Patients Undergoing Ablation for 
Atrial Fibrillation (AF), Anticoagulation With 
Uninterrupted Dabigatran was Associated With Fewer 
Bleeding Complications than Uninterrupted Warfarin 
Among 635 AF patients undergoing ablation, 
randomized to uninterrupted dabigatran (150 mg bid) or 
warfarin (target INR, 2.0 to 3.0) for 4-8 weeks prior and 8 
weeks after ablation, the incidence of major bleeding 
events during and up to 8 weeks after ablation was lower 
with dabigatran than with warfarin (5 patients - 1.6% vs 22 
patients - 6.9%; P<0.001). Dabigatran was associated with 
fewer periprocedural pericardial tamponades and groin 
hematomas than warfarin. The two treatment groups had a 
similar incidence of minor bleeding events. One 
thromboembolic event occurred in the warfarin group. 
(Calkins H et al, N Engl J Med 2017; 376:1627-1636).   
iFR-SWEDEHEART: Among Patients With Stable 
Angina or Acute Coronary Syndrome, an iFR-Guided 
Revascularization Strategy was Noninferior to an FFR-
Guided Revascularization Strategy  
The instantaneous wave-free ratio (iFR) is an index 
used to assess the severity of coronary-artery stenosis. 
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Among 2037 participants with stable angina or an acute 
coronary syndrome who had an indication for 
physiologically guided assessment of coronary-artery 
stenosis, randomly assigned to undergo revascularization 
guided by iFR or FFR, a primary end-point event (death 
from any cause, nonfatal MI, or unplanned revasculari-
zation within 12 months) occurred in 68 of 1012 patients 
(6.7%) in the iFR group and in 61 of 1007 (6.1%) in the 
FFR group (P=0.007 for noninferiority; hazard ratio, 1.12; 
P=0.53); The rates of myocardial infarction, target-lesion 
revascularization, restenosis, and stent thrombosis did not 
differ significantly between the two groups. A significantly 
higher proportion of patients in the FFR group than in the 
iFR group reported chest discomfort during the procedure 
(Götberg M et al; N Engl J Med 2017; 376:1813-1823).   
DEFINE-FLAIR: Coronary Revascularization Guided 
by iFR was Noninferior To Revascularization Guided 
by FFR / The Rate of Adverse Procedural Signs and 
Symptoms was Lower and the Procedural Time was 
Shorter With iFR Than With FFR  
Among 2492 randomly assigned patients with coronary 
artery disease to undergo either iFR-guided or FFR-guided 
coronary revascularization, at 1 year, the primary end point 
(death, nonfatal MI, or unplanned revascularization) had 
occurred in 78 of 1148 patients (6.8%) in the iFR group 
and in 83 of 1182 patients (7%) in the FFR group (P<0.001 
for noninferiority; hazard ratio, 0.95; P=0.78). The risk of 
each component of the primary end point and of death from 
cardiovascular or non-cardiovascular causes did not differ 
significantly between the groups. The number of patients 
who had adverse procedural symptoms and clinical signs 
was significantly lower in the iFR than in the FFR group 
(39 patients - 3.1% vs 385 patients -30.8%, P<0.001), and 
the median procedural time was significantly shorter (40.5 
minutes vs 45.0 min, P=0.001) (Davies JE et al, N Engl J 
Med 2017; 376:1824-1834).    
ACCELERATE: The Cholesteryl Ester Transfer 
Protein (CETP) Inhibitor Evacetrapib Failed to 
Reduce Cardiovascular Events  
Among 12,092 patients with atherosclerotic disease 
randomly assigned to receive either evacetrapib (130 mg 
qd) or matching placebo, although at 3 months, a 31.1% 
decrease in the mean LDL cholesterol level was observed 
with evacetrapib vs a 6% increase with placebo, and a 
133.2% increase in the mean HDL cholesterol level was 
seen with evacetrapib vs a 1.6% increase with placebo, the 
study was terminated early because of a lack of efficacy. 
After a median of 26 months of evacetrapib or placebo, a 
primary end-point event (death from cardiovascular 
causes, MI, stroke, coronary revascularization, or 
hospitalization for unstable angina) occurred in 12.9% of 
the patients in the evacetrapib group and in 12.8% of those 
in the placebo group (hazard ratio, 1.01; P=0.91) (Linkoff 
AM et al, N Engl J Med 2017;376:1933-1942).   
AIDA: Bioresorbable Scaffolds Fail to Reduce the Rate 
of Target-Vessel Failure Compared to Metallic Stents, 
while they Confer a Higher Incidence of Device 
Thrombosis  
Among 1845 patients undergoing PCI randomly 
assigned to receive either a bioresorbable vascular scaffold 
(924 patients) or a metallic stent (921 patients), over a 
median of 707 days, target-vessel failure occurred in 105 
patients in the scaffold group and in 94 patients in the stent 
group (2-year cumulative event rates, 11.7% and 10.7%, 
respectively; hazard ratio, 1.12; P=0.43), cardiac death in 
18 vs 23 patients (2-year cumulative event rates, 2.0% and 
2.7%, respectively), target-vessel MI in 48 vs 30 patients 
(2-year cumulative event rates, 5.5% and 3.2%), and 
target-vessel revascularization in 76 vs 65 patients (2-year 
cumulative event rates, 8.7% and 7.5%). Definite or 
probable device thrombosis occurred in 31 patients in the 
scaffold group as compared with 8 patients in the stent 
group (2-year cumulative event rates, 3.5% vs 0.9%; 
hazard ratio, 3.87; P<0.001) (Wykrzykowska JJ et al, N 
Engl J Med 2017;376:2319-2328).    
Rapid Rule Out of AMI: A Single hs-cTnT 
Concentration Below the Limit of Detection (<0.005 
µg/L) in Combination With a Nonischemic ECG May 
Successfully Rule Out AMI in Patients Presenting to 
Emergency Departments (EDs) With Possible 
Emergency Acute Coronary Syndrome  
Of 9241 patients, in 11 cohort studies, presenting to the 
ED with possible acute coronary syndrome, 2825 (30.6%) 
were classified as low risk (no new ischemia on ECG and 
hs-cTnT measurements <0.005 µg/L). Fourteen (0.5%) 
low-risk patients had AMI. Sensitivity of the risk 
classification for AMI ranged from 87.5% to 100% in 
individual studies. Pooled estimated sensitivity was 
98.7%. Sensitivity for 30-day major adverse cardiac events 
(MACEs) ranged from 87.9% to 100%; pooled sensitivity 
was 98%. No low-risk patients died (Pickering JW et al, 
Ann Intern Med 2017;166:715-724).  
 
GEMINI-ACS-1: A Dual Pathway Antithrombotic 
Therapy Combining Low-Dose Rivaroxaban With A 
P2Y12 Inhibitor for the Treatment of Patients With 
Acute Coronary Syndromes Had Similar Risk of 
Bleeding as Aspirin and a P2Y12 Inhibitor  
Among 3037 patients with acute coronary syndromes 
randomly assigned to receive aspirin 100 mg qd (n=1518) 
or rivaroxaban 2.5 mg bid (n=1519) in addition to 
clopidogrel or ticagrelor, with 1704 patients (56%) in the 
ticagrelor and 1333 (44%) in the clopidogrel strata, over 
median 291 days, TIMI non-CABG clinically significant 
57 
 
bleeding was similar with rivaroxaban vs aspirin therapy 
(total 154 patients - 5%; 80 participants - 5% of 1519 vs 74 
participants - 5% of 1518; HR 1·09; p=0.5840) (Ohman 
EN et al, Lancet 2017; 389(10081):1799-1908). 
 
ONTARGET & TRANSCEND Trials: The Lowest 
Blood Pressure Possible is not Necessarily the Optimal 
Target for High-Risk Patients / Mean Achieved SBP < 
120 mmHg was Associated With Increased Risk of 
Cardiovascular Outcomes Except for MI and Stroke 
Among 30 937 patients followed up for a median of 56 
months, baseline systolic blood pressure (SBP) >140 
mmHg was associated with greater incidence of all 
outcomes compared with 120 mmHg to <140 mmHg. By 
contrast, a baseline diastolic blood pressure (DBP) <70 
mmHg was associated with the highest risk for most 
outcomes compared with all DBP categories >70 mm Hg. 
In 4052 patients with SBP <120 mmHg, the risk of the 
composite cardiovascular outcome (adjusted hazard ratio-
HR 1.14), cardiovascular death (1.29), and all deaths 
(1.28) were increased compared with those in whom SBP 
was 120–140 mm Hg (HR 1 for all outcomes, n=16099). 
No harm or benefit was observed for MI, stroke, or hospital 
admission for heart failure. Mean achieved SBP more 
accurately predicted outcomes than baseline or time-
updated SBP, and was associated with the lowest risk at 
~130 mmHg, and at 110–120 mmHg risk increased for the 
combined outcome, cardiovascular death, and all-cause 
death except stroke. A mean DBP <70 mmHg (n=5352) 
was associated with greater risk of the composite primary 
outcome (HR 1.31), MI (1.55), hospital admission for heart 
failure (1.59) and all-cause death (1.16) than a DBP 70–80 
mmHg (n=14,305). A pretreatment and mean on-treatment 
DBP of ~75 mmHg was associated with the lowest risk 
(Bohm M et al, Lancet 2017; 389 (10085):2226-2237).  
 
RESOLVE & SAVORY Registries: Subclinical Leaflet 
Thrombosis was Frequent in Bioprosthetic Aortic 
Valves, More Common in Transcatheter than in 
Surgical Valves, Best Prevented or Managed with Oral 
Anticoagulants, But not Dual Antiplatelet Therapy  
Of the 890 (96%) with interpretable CT scans, 106 
(12%) patients had subclinical leaflet thrombosis, 
including 5 (4%) of 138 with thrombosis of surgical valves 
vs 101 (13%) of 752 with thrombosis of transcatheter 
valves (p=0.001). The median time from aortic valve 
replacement to CT for the entire cohort was 83 days. 
Subclinical leaflet thrombosis was less frequent among 
patients receiving anticoagulants (8 - 4% of 224) than 
among those receiving dual antiplatelet therapy (31 - 15% 
of 208; p<0·0001); NOACs were equally as effective as 
warfarin (3 - 3% of 107 vs 5 - 4% of 117; p=0·72). 
Subclinical leaflet thrombosis resolved in 36 (100%) of 36 
patients (warfarin 24 - 67%; NOACs 12 -33%) receiving 
anticoagulants, whereas it persisted in 20 (91%) of 22 
patients not receiving anticoagulants (p<0·0001). A 
greater proportion of patients with subclinical leaflet 
thrombosis had aortic valve gradients of >20 mmHg and 
increases in aortic valve gradients of >10 mmHg (12-14% 
of 88) than did those with normal leaflet motion (7-1% of 
632; p<0·0001). Although stroke rates were not different 
between those with or without reduced leaflet motion, 
subclinical leaflet thrombosis was associated with 
increased rates of TIAs and all strokes or TIAs 
(Chakravarty T et al, Lancet 2017;389:2383-92).   
Important Review and Other Articles  
Advanced heart failure and ventricular arrhythmias 
(Santangeli P et al, J Am Coll Cardiol 2017;69:1842-60), 
Antiplatelet therapy and noncardiac surgery (Banerjee S et 
al, J Am Coll Cardiol 2017;69:1861-70), Modifiable risk 
factors for AF (Du X et al, J Am Coll Cardiol 2017;69: 
1968–82), Transcatheter mitral valve replacement 
(Regueiro A et al, J Am Coll Cardiol 2017;69:2175–92), 
Bioprosthetic valve thrombosis (Puri R et al, J Am Coll 
Cardiol 2017;69:2193-2211), Antiphospholipid syndrome 
(Corban MT et al, J Am Coll Cardiol 2017;69:2317-30), 
Ultrafiltration therapy in heart failure (Costanzo MR et al, 
J Am Coll Cardiol 2017;69:2428-45), Novel antidiabetic 
drugs (Sattar N et al, J Am Coll Cardiol 2017;69:2646-56), 
Left ventricular assist devices (Pinney SP et al, J Am Coll 
Cardiol 2017;69:2845-61), 2017 ACC/AHA Advanced 
Training Statement on Advanced Heart Failure and 
Transplant Cardiology (Jessup M et al, J Am Coll Cardiol 
2017;69:2977-3001), HIV-associated atherosclerosis 
(Kearns A et al, J Am Coll Cardiol 2017;69:3084-98), 
Physiologic pacing (Vijayaraman P et al, J Am Coll 
Cardiol 2017;69:3099-3114), Cardiac amyloidosis 
(Maurer MS et al, Circulation 2017;135:1357-77), 
Leadless cardiac pacing (Tjong FVY et al, Circulation 
2017; 135:1458-1470), AF and heart failure (Verma A et 
al, Circulation 2017;135:1547-63), Kawasaki disease 
(McCrindle BW et al, Circulation 2017;135:e927-e999), 
Aortic valve bioprostheses (Holmes DR et al, Circulation 
2017;135:1749-56), Cardiovascular safety of non-steroidal 
anti-inflammatory agents (Antman EM, Circulation 
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